Abstract:Abstract Background/Aims Palindromic rheumatism (PR) is a recognised precursor of rheumatoid arthritis (RA). Up to 50% of PR patients will progress to persistent inflammatory arthritis (PIA) but risk factors for progression remain unclear. Analysis of this large UK prospective PR cohort has been used to develop the first risk stratification tool to predict progression to PIA. Methods The Leeds PR cohort was recruited from regional primary and secondary care referrals. PR was defined as ‘a confirmed history/physical examination consistent with episodes of joint pain and swelling that returned to normal in the absence of an alternative diagnosis’. Clinical, serological and immunogenetic parameters were assessed at baseline and three monthly for the first year, then six monthly. Progression to PIA was defined as clinical synovitis persisting for >3 weeks as confirmed by a rheumatologist. Prediction models were developed by performing a Cox regression analysis, then applying LASSO to select the most important risk variables (using R). Results 161 PR patients were followed between July 2008 and January 2023. 33% (53/161) developed PIA and 91% of progressors met criteria for RA. 90% of patients were DMARD naive at baseline. Female gender, anti-cyclic citrullinated peptide (anti-CCP) positivity, rheumatoid factor (RF) positivity, age>40, smoking (ever) and a typical interval between attacks of < 1 month were all associated with progression (Table 1). Cox regression analysis showed female gender (HR 2.2CI1.1-4.7, p = 0.03) and anti-CCP>3x upper limit of normal (HR 5.9, CI 2.0-17.4, p = 0.002) were strongly associated with progression. 'Ever’ and 'Two-year’ prediction models were created to calculate risk of developing PIA (Table 1). Patients could be stratified into high, moderate and low risk groups, with progression rates of 53% (34/64), 25% (19/77) and 0% respectively in the ‘Ever’ model and 37% (27/ 73), 16% (11/69) and 0% respectively in the ‘Two-year’ model. Conclusion In patients with PR, female gender, positive anti-CCP, positive RF, age >40, smoking and a typical interval between attacks of < 1 month were predictive of progression to PIA. Combining these factors allows feasible risk stratification in clinical practice. High and moderate risk groups should be monitored in secondary care and considered for interventional trials. Disclosure R. Chowdhury: None. F. Shuweihdi: None. N. Sidhu: None. L. Duquenne: None. L. Garcia-Montoya: None. J. Nam: None. A. Di Matteo: None. K. Harnden: None. D. Sahin-Eroglu: None. P. Emery: Consultancies; BMS, AbbVie, MSD, Pfizer, Novartis, and Roche. Honoraria; Abbvie, Gilead, Lilly, Novartis. Grants/research support; AbbVie, BMS, Lilly, Samsung. K. Mankia: Honoraria; Abbvie, Lilly, UCB, Galapagos. Grants/research support; Gilead, Lilly.

Performance of existing diagnostic criteria for palindromic rheumatism

How should we treat palindromic rheumatism? A systematic literature review

Assessing the Immune Cell Subset and Genetic Mutations in Patients With Palindromic Rheumatism Seronegative for Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide

Classification Criteria of Early Rheumatoid Arthritis and Validation of Its Performance in A Multi-Centre Cohort

P128 Predicting Persistent Inflammatory Arthritis in patients with Palindromic Rheumatism: Development of Scores for Risk Stratification

Performance Des Critères De L’american College of Rheumatology/European League Against Rheumatism 2010 Dans Le Diagnostic De La Polyarthrite Rhumatoïde Chez Les Patients Chinois

Performance of the Revised Classification Criteria for Systemic Autoimmune Rheumatic Diseases and Their Overlap Syndromes

Performance of the classification criteria for early rheumatoid arthritis in a multi-center cohort

Validation of New Classification Criteria of Rheumatoid Arthritis in an International Multicentre Study.

The Ratchet Model of Synovial Flares in Palindromic Rheumatism

Detection of systemic autoimmune diseases in an ongoing assessment program for hand arthralgias. A comparative analysis with inflammatory and non-inflammatory arthropathies

Clinical Validation of the 2012 Classification Criteria for Early Rheumatoid Arthritisin: a Domestic Multi-Center Cohort

European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance

Research on Syndrome Diagnostic Evaluation Criteria in Rheumatoid Arthritis Based on Multivariate Statistical Analysis

PROMIS-29 in rheumatoid arthritis patients who screen positive or negative for fibromyalgia on MDHAQ FAST4 (fibromyalgia assessment screening tool) or 2011 fibromyalgia criteria

Performance of the American College of Rheumatology/European League Against Rheumatism 2010 Criteria for the Diagnosis of Rheumatoid Arthritis in Chinese Patients.

Comparison of Clinical Remission Criteria of Rheumatoid Arthritis and Discussion about the Practicability in Clinical Practice

Comparison of Three Classification Criteria of Rheumatoid Arthritis in an Inception Early Arthritis Cohort.

Concordance and agreement between different activity scores in polymyalgia rheumatica

Psychometric Properties of Patient-reported Outcome Measures to Assess Resilience in Individuals with Musculoskeletal Pain or Rheumatic Conditions: A COSMIN-based Systematic Review

The Performance Of 2023 American College Of Rheumatology (Acr) / European Alliance Of Associations For Rheumatology (Eular) Antiphospholipid Syndrome Classification Criteria In A Real-World Rheumatology Department